Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
Status: | Active, not recruiting |
---|---|
Conditions: | Breast Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 1/5/2019 |
Start Date: | June 14, 2016 |
End Date: | July 31, 2020 |
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
The purpose of this study is determine if the triplet combination of ribociclib, everolimus
and exemastane is effective in the treatment of locally advanced/metastatic breast cancer
following treatment with a CDK 4/6 inhibitor
and exemastane is effective in the treatment of locally advanced/metastatic breast cancer
following treatment with a CDK 4/6 inhibitor
The purpose of the phase I dose escalation part of this study is to estimate the MTD(s)
and/or identify the RP2D of the combination treatment of ribociclib+ everolimus + exemestane
when dosed continuously in adult men and postmenopausal women with HR+ HER2-negative advanced
breast cancer resistant to the non-steroidal aromatase inhibitors, fulvestrant or tamoxifen.
The purpose of the phase II portion of this trial will be to evaluate the anti-tumor activity
of exemestane, everolimus and ribociclib triplet following progression on a CDK 4/6
inhibitor. This part of the study will be conducted using a Simon's optimal two-stage design.
and/or identify the RP2D of the combination treatment of ribociclib+ everolimus + exemestane
when dosed continuously in adult men and postmenopausal women with HR+ HER2-negative advanced
breast cancer resistant to the non-steroidal aromatase inhibitors, fulvestrant or tamoxifen.
The purpose of the phase II portion of this trial will be to evaluate the anti-tumor activity
of exemestane, everolimus and ribociclib triplet following progression on a CDK 4/6
inhibitor. This part of the study will be conducted using a Simon's optimal two-stage design.
Inclusion Criteria:
- Adult men and women
- Patient has a confirmed diagnosis of estrogen-receptor positive and/or progesterone
receptor positive breast cancer by local laboratory and has HER2-negative breast
cancer
- Patient must have either measurable disease by RECIST 1.1 or bone lesions in absence
of measurable disease.
- ECOG Performance Status 0 - 1
- Disease refractory to either, AI, tamoxifen or fulvestrant
- Previously treated on any CDK 4/6 inhibitor.
- Patient has adequate bone marrow and organ function.
Exclusion Criteria:
- Patient with symptomatic visceral disease or any disease burden that makes the patient
ineligible for endocrine therapy per the investigator's best judgment.
- Patient has received more than one line of chemotherapy for advanced disease.
- Previous treatment with mTOR inhibitors, or exemestane for advanced disease.
- Progressed on more than one CDK 4/6 inhibitor
- Patient with CNS involvement unless they are at least 4 weeks from prior therapy
completion.
- Clinically significant, uncontrolled heart disease and/or recent cardiac events.
We found this trial at
27
sites
Detroit, Michigan 48202
Principal Investigator: Haythem Ali
Phone: 313-916-1784
Click here to add this to my saved trials
441 North Lakeview Avenue
Anaheim, California 92807
Anaheim, California 92807
Principal Investigator: Jennifer Carney
Phone: 808-432-8587
Click here to add this to my saved trials
Atlanta, Georgia 30342
Principal Investigator: Amelia Zelnak
Phone: 770-496-9420
Click here to add this to my saved trials
Boston, Massachusetts 02114
Principal Investigator: Aditya Bardia
Phone: 617-643-2208
Click here to add this to my saved trials
Chandler, Arizona 85224
Principal Investigator: Mikhail I. Shtivelband
Click here to add this to my saved trials
Davie, Florida 33328
Principal Investigator: Elizabeth Tan-Chiu
Phone: 954-582-1850
Click here to add this to my saved trials
Click here to add this to my saved trials
Fort Myers, Florida 33916
Principal Investigator: Lowell Hart
Phone: 239-274-9930
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
Principal Investigator: Cristina Truica
Phone: 717-531-8678
Click here to add this to my saved trials
Houston, Texas 77024
Principal Investigator: Julio Peguero
Phone: 713-600-0992
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Meghan Sri Karuturi
Click here to add this to my saved trials
Kansas City, Missouri 64111
Principal Investigator: Timothy Pluard
Phone: 816-932-1601
Click here to add this to my saved trials
Kansas City, Missouri 64132
Principal Investigator: Stephanie L Graff
Phone: 816-276-4700
Click here to add this to my saved trials
94 Old Short Hills Road
Livingston, New Jersey 07039
Livingston, New Jersey 07039
(973) 322-5000
Principal Investigator: Andrew Brown
Phone: 973-322-5000
Saint Barnabas Medical Center As a Barnabas Health facility, Saint Barnabas Medical Center is committed...
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Sara Alsterlind Hurvitz
Click here to add this to my saved trials
250 25th Avenue North
Nashville, Tennessee 37203
Nashville, Tennessee 37203
Principal Investigator: Denise A. Yardley
Phone: 615-329-7274
Click here to add this to my saved trials
New Haven, Connecticut 06520
Principal Investigator: Tara Sanft
Phone: 203-737-8309
Click here to add this to my saved trials
Orlando, Florida 32806
Principal Investigator: Rebecca Moroose
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Amy Clark
Click here to add this to my saved trials
Redondo Beach, California 90277
Principal Investigator: David Chan
Phone: 310-750-3376
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Cynthia X. Ma
Phone: 314-362-7249
Click here to add this to my saved trials
1201 5th Avenue North
Saint Petersburg, Florida 33705
Saint Petersburg, Florida 33705
Principal Investigator: Gail L Wright
Phone: 727-216-1143
Click here to add this to my saved trials
Click here to add this to my saved trials
San Francisco, California 94143
Principal Investigator: Hope S Rugo
Click here to add this to my saved trials
Santa Maria, California 93454
Principal Investigator: Robert Dichmann
Click here to add this to my saved trials
Tacoma, Washington 98405
Principal Investigator: Sibel Blau
Phone: 253-383-3366
Click here to add this to my saved trials
Westwood, Kansas 66205
Principal Investigator: Qamar J Khan
Phone: 913-588-2567
Click here to add this to my saved trials